Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)-Reference-Cited by-同舟云学术

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

Published:2024-02-04 Issue: Volume: Page:
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

McCormack Meredith,Paczkowski Rosirene,Gronroos Noelle N.^ORCID,Noorduyn Stephen G.^ORCID,Lee Lydia^ORCID,Veeranki Phani^ORCID,Johnson Mary G.,Igboekwe Emmeline,Kahle-Wrobleski Kristin,Panettieri Reynold

Funder

GSK

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02776-8.pdf

Reference24 articles.

1. Tkacz J, Evans KA, Touchette DR, et al. PRIMUS – Prompt Initiation of Maintenance Therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:329–42.

2. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. 2023. https://goldcopd.org/2023-gold-report-2/. Accessed 13 July 2023.

3. Larsen DL, Gandhi H, Pollack M, Feigler N, Patel S, Wise RA. The quality of care and economic burden of COPD in the United States: considerations for managing patients and improving outcomes. Am Health Drug Benefits. 2022;15(2):57–64.

4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. 2022. https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed 22 Aug 2023.

5. Stanford RH, Parker ED, Reinsch TK, Buikema AR, Blauer-Peterson C. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA. Respir Med. 2019;150:1–7.